Formulary Watch |

EpiPens have been in short supply, but stakeholders are trying to fill in the access gap.

FDA warns opioid repackers for "significant violations."

FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

The validity of a new large study linking anticholinergic drugs to the risk of dementia has stirred up controversy.

FDA recalls insulin pumps due to cybersecurity miscommunication.

A women’s health organization is concerned about the safety and effectiveness of bremelanotide (Vyleesi) after FDA approved it to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.

A new report from OptumRx reveals the top 4 drugs in development for the second quarter of 2019.

The first FDA-approved device to reduce functional abdominal pain in younger patients with irritable bowel syndrome is now available to medical providers.

A record number of new oncology treatments launched in the US last year and spending on cancer drugs soared. Here are the top 6 cancer drug trends revealed in the report.

FDA cleared the first-and-only calcitonin gene-related peptide (CGRP) antibody for cluster headaches.

The first respiratory biologic to be approved for administration via an autoinjector will be available in the US soon.

FDA cleared alpelisib (Piqray), the first PI3K inhibitor to treat breast cancer, to be used in combination with fulvestrant (Faslodex).

FDA granted market authorization for a non-invasive, smartphone device that offers respite from migraines.

Express Scripts, a Cigna company, plans to launch the industry's first stand-alone digital health formulary.

FDA approved some important new therapies, including the first anticoagulant for children, an injectable for diabetic retinopathy, and a treatment for renal cell carcinoma.

Generic drug makers are defending their practices after 44 US states accused Teva Pharmaceuticals and other pharma makers of conspiring to inflate their prices in a lawsuit.

A new government rule requiring pharma makers to disclose drug prices in television ads will likely create more confusion for consumers, analysts and organizations said.

Stronger warnings on popular insomnia medications could have an impact on prescribing, some experts say.

While FDA approved the second biosimilar drug to Enbrel, the success of the medication hinges on a pending lawsuit. 

CDC commentary claims patients taken off opiods too soon.

A new report determines the trends fueling drug research and development over the past 10 years-and into the future.

FDA cleared the first medical device to treat attention deficit hyperactivity disorder (ADHD) in kids.

A Commonwealth Fund study has revealing findings about PBMs’ use of rebates and impact on drug prices.

Metastatic breast cancer drug expands treatment to men.

FDA cleared Dovato (ViiV Healthcare), the first 2-drug regimen to treat HIV-1 in adults with no antiretroviral treatment history.

FDA fast-tracks biosimiliar insulin products to elevate competition.

FDA approved 2 new multiple sclerosis drugs. Here's what you should know about them.

Postpartum drug is a game changer, but can women afford it?